The Effects of 2′-O-Methoxyethyl Oligonucleotides on Renal Function in Humans
Open Access
- 1 February 2018
- journal article
- research article
- Published by Mary Ann Liebert Inc in Nucleic Acid Therapeutics
- Vol. 28 (1), 10-22
- https://doi.org/10.1089/nat.2017.0693
Abstract
Systemically administered 2′-O-methoxyethyl (2′MOE) antisense oligonucleotides (ASOs) accumulate in the kidney and metabolites are cleared in urine. The effects of eleven 2′MOE ASOs on renal function were assessed in 2,435 patients from 32 phase 2 and phase 3 trials. The principle analysis was on data from 28 randomized placebo-controlled trials. Mean levels of renal parameters remained within normal ranges over time across dose groups. Patient-level meta-analyses demonstrated a significant difference between placebo-treated and 2′MOE ASO-treated patients at doses >175 mg/week in the percentage and absolute change from baseline for serum creatinine and estimated glomerular filtration rate. However, these changes were not clinically significant or progressive. No dose-related effects were observed in the incidence of abnormal renal test results in the total population of patients, or subpopulation of diabetic patients or patients with renal dysfunction at baseline. The incidence of acute kidney injury [serum creatinine ≥0.3 mg/dL (26.5 μM) increases from baseline or ≥1.5 × baseline] in 2′MOE ASO-treated patients (2.4%) was not statistically different from placebo (1.7%, P = 0.411). In conclusion, in this database, encompassing 32 clinical trials and 11 different 2′MOE ASOs, we found no evidence of clinically significant renal dysfunction up to 52 weeks of randomized-controlled treatment.Keywords
This publication has 18 references indexed in Scilit:
- Cardiovascular and Metabolic Effects of ANGPTL3 Antisense OligonucleotidesThe New England Journal of Medicine, 2017
- The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical TrialsNucleic Acid Therapeutics, 2017
- Renin–Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection FractionCirculation: Heart Failure, 2017
- Pharmacology of Antisense DrugsAnnual Review of Pharmacology and Toxicology, 2017
- Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in MonkeysNucleic Acid Therapeutics, 2016
- Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trialsThe Lancet, 2016
- Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in MiceMolecular Therapy Nucleic Acids, 2016
- Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 studyThe Lancet, 2015
- Transthyretin Amyloidosis and the KidneyClinical Journal of the American Society of Nephrology, 2012
- A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction EquationAnnals of Internal Medicine, 1999